Dewpoint

Dewpoint Therapeutics is a Boston-based biotechnology company, founded in 2018, that pioneers drug discovery based on biomolecular condensates — the membraneless compartments inside cells whose formation and dysregulation underlie many diseases. Its condensate platform combines cell biology, high-throughput screening, and machine learning to identify condensate-modulating drugs (c-mods) against previously undruggable targets across oncology, neurodegeneration, and virology. Dewpoint is backed by SoftBank Vision Fund 2 and completed a $150M Series C in 2022. The company operates as a therapeutics developer and, as of this profile, exposes no public developer API, documentation, or developer portal; this entry captures its identity within the API Evangelist network.

Dewpoint is profiled on the APIs.io network. Tagged areas include Company, Health Tech, Biotech, Drug Discovery, and Pharmaceuticals.

🌐 Visit website 📡 Source on GitHub

5.7/100 minimal ▬ flat Agent 0/100 human only Full breakdown ↓
scored 2026-07-27 · rubric v0.5

0 APIs

CompanyHealth TechBiotechDrug DiscoveryPharmaceuticalsLife SciencesMachine Learning

Kin Score

Kin Score How this is scored →
scored 2026-07-27 · rubric v0.5

Composite quality — 5.7/100 · minimal

Contract Quality 0.0 / 25

Developer Ergonomics 0.0 / 20

Commercial Clarity 0.0 / 20

Operational Transparency 0.0 / 13

Governance 0.0 / 12

Discoverability 6.8 / 10

Agent readiness — 0/100 · human only

Machine-Readable Contract 0 / 18

Agentic Access Contract 0 / 15

MCP Server 0 / 12

Machine-Readable Auth 0 / 10

Idempotency 0 / 9

Stable Error Semantics 0 / 8

Request/Response Examples 0 / 7

Rate-Limit Signaling 0 / 7

Typed Event Surface 0 / 6

Agent Skills 0 / 5

Well-Known Catalog 0 / 4

Consent & Bot Identity 0 / 3

Improve this rating by publishing the missing artifacts — every area above can be raised, and the full rubric is at apis.io/rating/. This rating is computed from github.com/api-evangelist/dewpoint: open an issue to ask a question, or submit a pull request to add artifacts. Want it done for you? Prioritized profiling — $2,500 →

Resources

Company 1

The organization behind the API

Website

Website

Source (apis.yml)

aid: dewpoint
accessModel:
  pricing: unknown
  onboarding: unknown
  trial: false
  try_now: false
  public: false
  label: Unknown
  confidence: low
  source: []
  generated: '2026-07-22'
  method: derived
image: https://kinlane-images.s3.amazonaws.com/shared/apis-json/icons/dewpoint.png
name: Dewpoint
description: Dewpoint Therapeutics is a Boston-based biotechnology company, founded in 2018, that pioneers drug discovery
  based on biomolecular condensates — the membraneless compartments inside cells whose formation and dysregulation underlie
  many diseases. Its condensate platform combines cell biology, high-throughput screening, and machine learning to identify
  condensate-modulating drugs (c-mods) against previously undruggable targets across oncology, neurodegeneration, and virology.
  Dewpoint is backed by SoftBank Vision Fund 2 and completed a $150M Series C in 2022. The company operates as a therapeutics
  developer and, as of this profile, exposes no public developer API, documentation, or developer portal; this entry captures
  its identity within the API Evangelist network.
url: https://raw.githubusercontent.com/api-evangelist/dewpoint/refs/heads/main/apis.yml
humanURL: https://dewpointx.com/
x-type: company
x-source: vc-portfolio
x-backed-by:
- softbank-vision-fund
x-tier: stub
x-tier-reason: portfolio-lead
specificationVersion: '0.20'
created: '2026-07-17'
modified: '2026-07-18'
tags:
- Company
- Health Tech
- Biotech
- Drug Discovery
- Pharmaceuticals
- Life Sciences
- Machine Learning
apis: []
common:
- type: Website
  url: https://dewpointx.com/
maintainers:
- FN: Kin Lane
  email: kin@apievangelist.com
- FN: APIs.json
  email: info@apis.io
x-enrichment:
  date: '2026-07-19'
  status: backfilled
  pass: local-v1
  note: backfilled from .gitignore signal + verified work evidence